CNS Disorders  >>  padsevonil (UCB0942)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
padsevonil (UCB0942) / UCB
NCT03695094: A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

Completed
1
31
Europe
Padsevonil, PSL, UCB0942, Oxcarbazepine, OXC, Levetiracetam, LEV, Lamotrigine, LTG, Brivaracetam, BRV
UCB Biopharma S.P.R.L.
Epilepsy
05/19
05/19
NCT04283136: A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on Padsevonil

Withdrawn
1
0
NA
Padsevonil type 1 Tablet 200 mg, Padsevonil type 2 Tablet, Padsevonil type 3 Tablet, Padsevonil type 4 Tablet, Padsevonil type 5 Tablet
UCB Biopharma SRL
Healthy Participants, Epilepsy
05/20
05/20
ChiCTR2000041476: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PADSEVONIL IN HEALTHY CHINESE SUBJECTS

Recruiting
1
14
 
Padsevonil(PSL) 200 mg ;placebo
West China Hospital, Sichuan University; UCB Biopharma SPRL, UCB Biopharma SPRL
epilepsy
 
 

Download Options